Indefinite Delivery Contract SPE2DX15D9357

This indefinite delivery contract, awarded by the U.S. Department of Defense's Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, aims to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military health facilities worldwide. The $499,999,999 single-award indefinite delivery contract (IDC) under the SPE2DB program enables the DLA to issue firm fixed-price delivery orders for branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables.

The task orders issued under this IDC cover a diverse portfolio of pharmaceutical items, including contraceptive devices like Mirena and Nexplanon, vaccines such as Gardasil and Trumenba, specialty medications like Botox, and common medical supplies like Surgilube lubricant. These delivery orders, valued up to several million dollars each, do not have any set-aside designations, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories and medical domains in support of the Department of Defense's healthcare requirements.